Long-term outcome of kidney transplantation in AL amyloidosis

被引:56
作者
Angel-Korman, Avital [1 ]
Stern, Lauren [1 ,3 ]
Sarosiek, Shayna [2 ,3 ]
Sloan, J. Mark [2 ,3 ]
Doros, Gheorghe [3 ,4 ]
Sanchorawala, Vaishali [2 ,3 ]
Havasi, Andrea [1 ,3 ]
机构
[1] Boston Med Ctr, Renal Sect, Dept Med, Boston, MA USA
[2] Boston Med Ctr, Sect Hematol & Oncol, Dept Med, Boston, MA USA
[3] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA 02118 USA
[4] Boston Univ, Sch Publ Hlth, Boston, MA USA
关键词
AL amyloidosis; ESRD; graft survival; hematologic response; renal transplantation; LIGHT-CHAIN AMYLOIDOSIS; HIGH-DOSE MELPHALAN; STEM-CELL TRANSPLANTATION; PRIMARY SYSTEMIC AMYLOIDOSIS; STAGE RENAL-DISEASE; BORTEZOMIB; DEXAMETHASONE; PREDNISONE; COLCHICINE; SURVIVAL;
D O I
10.1016/j.kint.2018.09.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapies for AL amyloidosis have dramatically improved, leading to longer patient survival; however, more AL amyloidosis patients are reaching end-stage renal disease (ESRD). There are no clear guidelines regarding eligibility for kidney transplantation in patients with AL amyloidosis, and data on outcomes are limited. We evaluated the clinical and laboratory data of 49 patients who were followed in the Amyloidosis Center at Boston University and underwent kidney transplantation at a center in the United States between 1987-2017. During a median follow-up of 7.2 years (range 0-19), the median patient survival from diagnosis was 15.4 years, and from kidney transplantation was 10.5 years. One, three, and five-year graft survival were 94%, 89%, and 81%, respectively. Patients with hematologic complete response or very good partial response prior to kidney transplantation had significantly better patient survival than patients with partial response or no response, and the median time to graft loss was 10.4 years versus 5.5 years, respectively. This is the largest published series of kidney transplantation in patients with AL amyloidosis, suggesting that kidney transplantation can have a good outcome in carefully selected patients, particularly in those who have achieved a complete response or very good partial response at the time of kidney transplantation.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 37 条
[1]   Presentation and outcome of patients with systemic amyloidosis undergoing dialysis [J].
Bollee, Guillaume ;
Guery, Bruno ;
Joly, Dominique ;
Snanoudj, Renaud ;
Terrier, Benjamin ;
Allouache, Mahmoud ;
Mercadal, Lucile ;
Peraldi, Marie-Noealle ;
Viron, Beatrice ;
Fumeron, Christine ;
Elie, Caroline ;
Fakhouri, Fadi .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (02) :375-381
[2]   Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis [J].
Comenzo, R. L. ;
Reece, D. ;
Palladini, G. ;
Seldin, D. ;
Sanchorawala, V. ;
Landau, H. ;
Falk, R. ;
Wells, K. ;
Solomon, A. ;
Wechalekar, A. ;
Zonder, J. ;
Dispenzieri, A. ;
Gertz, M. ;
Streicher, H. ;
Skinner, M. ;
Kyle, R. A. ;
Merlini, G. .
LEUKEMIA, 2012, 26 (11) :2317-2325
[3]  
Comenzo RL, 2007, CONTRIB NEPHROL, V153, P195
[4]   Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study [J].
Dispenzieri, A ;
Kyle, RA ;
Lacy, MQ ;
Therneau, TM ;
Larson, DR ;
Plevak, MF ;
Rajkumar, SV ;
Fonseca, R ;
Greipp, PR ;
Witzig, TE ;
Lust, JA ;
Zeldenrust, SR ;
Snow, DS ;
Hayman, SR ;
Litzow, MR ;
Gastineau, DA ;
Tefferi, A ;
Inwards, DJ ;
Micallef, IN ;
Ansell, SM ;
Porrata, LF ;
Elliott, MA ;
Gertz, MA .
BLOOD, 2004, 103 (10) :3960-3963
[5]   The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis [J].
Dispenzieri, Angela ;
Lacy, Martha Q. ;
Zeldenrust, Steven R. ;
Hayman, Suzanne R. ;
Kumar, Shaji K. ;
Geyer, Susan M. ;
Lust, John A. ;
Allred, Jacob B. ;
Witzig, Thomas E. ;
Rajkumar, S. Vincent ;
Greipp, Philip R. ;
Russell, Stephen J. ;
Kabat, Brian ;
Gertz, Morie A. .
BLOOD, 2007, 109 (02) :465-470
[6]   Renal risk and response in amyloidosis [J].
Dispenzieri, Angela .
BLOOD, 2014, 124 (15) :2315-2316
[7]   SYSTEMIC AMYLOIDOSIS INVOLVING 2 RENAL-TRANSPLANTS [J].
DORMAN, SA ;
GAMELLI, RL ;
BENZIGER, JR ;
TRAINER, TD ;
FOSTER, RS .
HUMAN PATHOLOGY, 1981, 12 (08) :735-738
[8]   KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients [J].
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 :S1-S155
[9]   Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [J].
Gertz, MA ;
Comenzo, R ;
Falk, RH ;
Fermand, JP ;
Hazenberg, BP ;
Hawkins, PN ;
Merlini, G ;
Moreau, P ;
Ronco, P ;
Sanchorawala, V ;
Sezer, O ;
Solomon, A ;
Grateau, G .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) :319-328
[10]   DIALYSIS SUPPORT OF PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS - A STUDY OF 211 PATIENTS [J].
GERTZ, MA ;
KYLE, RA ;
OFALLON, WM .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (11) :2245-2250